Research programme: CFTR channel modulators - Cystic Fibrosis Foundation Therapeutics/EPIX

Drug Profile

Research programme: CFTR channel modulators - Cystic Fibrosis Foundation Therapeutics/EPIX

Alternative Names: CFTR regulators - Cystic Fibrosis Foundation Therapeutics/EPIX

Latest Information Update: 16 Oct 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; EPIX Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cystic fibrosis

Most Recent Events

  • 01 Oct 2009 Discontinued - Preclinical for Cystic fibrosis in USA (unspecified route)
  • 08 Apr 2008 CFFT increases potential payments to EPIX under new agreement
  • 24 Jan 2008 EPIX receives milestone payment from Cystic Fibrosis Foundation Therapeutics for development of CFTR ion channel model
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top